Flavoprotein Fluorescence Correlation with Visual Acuity Response in Patients Receiving Anti-VEGF Injection for Diabetic Macular Edema

Table 2

Measurements pre- and postinjection. For each subject, all preinjection measurements were taken on the day of injection, and postinjection measurements were taken at a follow-up visit days later. BCVA = best corrected visual acuity; FPF = flavoprotein fluorescence; OCT = optical coherence tomography; CMT = central macular thickness; gsu = grayscale units.

Subject ID	Preinjection BCVA	Postinjection BCVA	Preinjection OCT CMT (μm)	Postinjection OCT CMT (μm)	Preinjection FPF (gsu)	Postinjection FPF (gsu)	Postinjection; follow-up visit; (days)	Injection position in current series
001	20/50	20/30	371.8	NA	437	272	7	2
006	20/150	20/100	582.2	518.8	181	156	14	1
008	20/100	20/70	574	541.2	589	506	28	3
007	20/60	20/50	392.8	334.4	574	505	56	1
011	20/150	20/400	594.4	NA	490	569	56	1
003	20/80	20/100	540	545.8	465	477	129	3
028	20/20	20/25	319	296	423	441	27	1
026	20/20	20/20	344.6	329.4	312	303	39	3